Personalis, Inc. (PSNL) stock
PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30379% above fair value
$15.71−0.15 (-0.95%)
Close on Nov 13, 2026Market cap $1.68BP/E –Yield –
Personalis cash
Cash and short-term investments held at the end of each period.
Personalis's cash was $190.60M at Sep 30, 2026. For fiscal 2025 it was $239.95M, up 29.7% from the year before. The highest annual figure on record is $287.06M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $239.95M | +29.7% |
| FY2024 | Dec 31, 2024 | $185.01M | +62.0% |
| FY2023 | Dec 31, 2023 | $114.18M | -31.9% |
| FY2022 | Dec 31, 2022 | $167.66M | -41.6% |
| FY2021 | Dec 31, 2021 | $287.06M | +41.2% |
| FY2020 | Dec 31, 2020 | $203.29M | +58.5% |
| FY2019 | Dec 31, 2019 | $128.29M | +549.8% |
| FY2018 | Dec 31, 2018 | $19.74M | -12.7% |
| FY2017 | Dec 31, 2017 | $22.62M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $190.60M | +26.6% |
| Q2 FY2026 | Jun 30, 2026 | $212.66M | +22.8% |
| Q1 FY2026 | Mar 31, 2026 | $233.22M | +25.6% |
| Q4 FY2025 | Dec 31, 2025 | $239.95M | +29.7% |
| Q3 FY2025 | Sep 30, 2025 | $150.52M | +4.8% |
| Q2 FY2025 | Jun 30, 2025 | $173.23M | +99.2% |
| Q1 FY2025 | Mar 31, 2025 | $185.69M | +94.6% |
| Q4 FY2024 | Dec 31, 2024 | $185.01M | +62.0% |
| Q3 FY2024 | Sep 30, 2024 | $143.65M | +19.1% |
| Q2 FY2024 | Jun 30, 2024 | $86.97M | -36.6% |
| Q1 FY2024 | Mar 31, 2024 | $95.42M | -35.9% |
| Q4 FY2023 | Dec 31, 2023 | $114.18M | -31.9% |
| Q3 FY2023 | Sep 30, 2023 | $120.66M | -37.4% |
| Q2 FY2023 | Jun 30, 2023 | $137.21M | -41.2% |
| Q1 FY2023 | Mar 31, 2023 | $148.94M | -44.1% |
| Q4 FY2022 | Dec 31, 2022 | $167.66M | -41.6% |
| Q3 FY2022 | Sep 30, 2022 | $192.76M | -36.8% |
| Q2 FY2022 | Jun 30, 2022 | $233.49M | -29.0% |
| Q1 FY2022 | Mar 31, 2022 | $266.54M | -24.6% |
| Q4 FY2021 | Dec 31, 2021 | $287.06M | +41.2% |
| Q3 FY2021 | Sep 30, 2021 | $305.23M | +48.1% |
| Q2 FY2021 | Jun 30, 2021 | $328.91M | +212.6% |
| Q1 FY2021 | Mar 31, 2021 | $353.43M | +194.4% |
| Q4 FY2020 | Dec 31, 2020 | $203.29M | +58.5% |
| Q3 FY2020 | Sep 30, 2020 | $206.06M | +61.9% |
| Q2 FY2020 | Jun 30, 2020 | $105.23M | -35.5% |
| Q1 FY2020 | Mar 31, 2020 | $120.03M | +507.9% |
| Q4 FY2019 | Dec 31, 2019 | $128.29M | +548.6% |
| Q3 FY2019 | Sep 30, 2019 | $127.28M | +462.7% |
| Q2 FY2019 | Jun 30, 2019 | $163.27M | – |
| Q4 FY2018 | Dec 31, 2018 | $19.74M | – |
| Q2 FY2018 | Jun 30, 2018 | $19.78M | – |
| Q4 FY2017 | Dec 31, 2017 | $22.62M | – |
See a number that looks wrong?